Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that on February 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 69,750 shares under the 2023 Inducement Option Plan, as amended.

Each option has an exercise price of $8.27 (closing price on February 2, 2026) and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and plan terms.

Key Figures

Inducement options granted: 69,750 shares Exercise price: $8.27 per share Vesting schedule: 25% after 1 year, remainder over 36 months +5 more

8 metrics

Inducement options granted 69,750 shares Nonstatutory stock options to four new employees

Exercise price $8.27 per share Closing price on February 2, 2026 for inducement options

Vesting schedule 25% after 1 year, remainder over 36 months Four-year vesting of inducement stock options

KOMZIFTI net product revenue $2.1 million From first sale (Nov 21–Dec 31, 2025)

Milestone payments $195 million Collaboration milestone payments reported Jan 11, 2026

Cash & short-term investments $667.3 million Balance as of Dec 31, 2025

Price vs 52-week high -40.75% Position relative to 52-week high of $12.49

Price vs 52-week low 36.78% Above 52-week low of $5.41

Market Reality Check

Price: $7.40 Vol: Volume 1,713,339 is 1.27x...

normal vol

$7.40 Last Close

Volume Volume 1,713,339 is 1.27x the 20-day average of 1,347,075. normal

Technical Shares at $7.40, trading below the 200-day MA at $8.18.

Peers on Argus

KURA fell 8.3% with several biotech peers also down (e.g., SANA -11.25%, AVBP -3...

KURA fell 8.3% with several biotech peers also down (e.g., SANA -11.25%, AVBP -3.26%, DAWN -2.51%, TNGX -2.29%), but no broad sector momentum signal was flagged.

Historical Context

5 past events · Latest: Jan 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 11	Commercial/financial update	Positive	-2.5%	FDA approval, KOMZIFTI launch, early revenues and 2026 milestones outlined.
Jan 05	Inducement option grants	Neutral	-7.7%	Stock options granted to new employees under 2023 Inducement Option Plan.
Dec 08	Clinical data update	Positive	-2.6%	KOMZIFTI triplet combination showed strong activity and manageable safety in AML.
Dec 03	Investor event announcement	Positive	+7.5%	Announcement of virtual investor event to discuss ASH 2025 triplet data.
Dec 02	Milestone payment	Positive	-2.7%	First U.S. KOMZIFTI sale triggering <b>$135M</b> milestone payment from Kyowa Kirin.

Pattern Detected

Recent KURA news has often been positive (approval, revenues, data) yet produced mixed to negative next-day price reactions, suggesting a tendency toward selling or muted responses after good news.

Recent Company History

Over the past few months, Kura Oncology has reported several milestones, including FDA approval and commercial launch of KOMZIFTI, a $135 million milestone payment, and strong combination data for ziftomenib. It also highlighted preliminary KOMZIFTI net product revenue of $2.1 million and cash and short-term investments of $667.3 million as of Dec 31, 2025. Despite these achievements, most of these announcements were followed by negative or modest stock reactions, framing today’s inducement grant within a backdrop of cautious trading.

Market Pulse Summary

This announcement details routine inducement stock option grants to four new employees under Kura On...

Analysis

This announcement details routine inducement stock option grants to four new employees under Kura Oncology’s 2023 Inducement Option Plan, with 69,750 options at an exercise price of $8.27 and a standard four-year vesting schedule. In the broader context, recent updates have highlighted FDA approval and commercial launch progress for KOMZIFTI, significant milestone payments, and strong combination data. Investors may watch future clinical milestones, commercialization metrics, and additional governance or compensation disclosures as key indicators of ongoing execution.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4), inducement option plan, exercise price

4 terms

nonstatutory stock options financial

"granted inducement awards consisting of nonstatutory stock options to purchase 69,750 shares"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

nasdaq listing rule 5635(c)(4) regulatory

"approved the stock options as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement option plan financial

"under the Company’s 2023 Inducement Option Plan, as amended"

A plan that grants stock options to newly hired or newly promoted employees and executives as a hiring or retention incentive, like offering a share of future upside instead of a higher salary. For investors this matters because these options can dilute existing shares, create ongoing compensation costs, and signal how management is being incentivized to grow the business—similar to giving a performance-based bonus that ties pay to company results.

exercise price financial

"Each stock option has an exercise price equal to $8.27 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 69,750 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $8.27 per share, the closing price of the Company’s common stock on February 2, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

How many shares did KURA grant in the February 2, 2026 inducement awards?

Kura granted a total of 69,750 stock options across four new employees. According to Kura Oncology, the awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The grants are subject to the 2023 Inducement Option Plan and option agreements.

What is the exercise price and vesting schedule for KURA's inducement options granted Feb 2, 2026?

Each option has an exercise price of $8.27, equal to the Feb 2, 2026 closing price. According to Kura Oncology, options vest over four years: 25% at the one-year anniversary, then monthly over the following 36 months, subject to continued service.

Why did KURA use Nasdaq Listing Rule 5635(c)(4) for the February 2026 grants?

The Compensation Committee approved the grants as inducement awards material to new hires under Nasdaq Listing Rule 5635(c)(4). According to Kura Oncology, this rule permits equity awards granted as an inducement to obtain new employees when approved by the committee.

Who received the inducement stock options disclosed by Kura on February 6, 2026?

The awards were granted to four new employees as inducement stock options under the company's plan. According to Kura Oncology, the grants are tied to each new hire's continued service and the terms of the applicable option agreements.

Do KURA’s inducement option grants on Feb 2, 2026 immediately dilute existing shareholders?

The grants create potential future dilution if exercised but do not immediately change outstanding common shares. According to Kura Oncology, the options must be exercised at $8.27 per share and vest over four years, subject to plan terms and service.